文献速递外周动脉疾病

慢性肢体威胁性缺血患者联合腹股沟上旁路与腹股沟下血运重建的当代结局

Contemporary outcomes of concomitant suprainguinal bypass with infrainguinal revascularization procedures in patients with chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2021-10-01

本研究基于血管质量倡议(VQI)数据库,回顾2010年1月至2020年6月接受腹股沟上旁路(SIB)的8037例慢性肢体威胁性缺血(CLTI)患者,比较单独SIB、SIB联合腹股沟下旁路(IIB)及SIB联合腹股沟下外周血管内介入(IIPVI)的结局。结果显示,静息痛患者联合血运重建围术期大截肢风险增加约2.8倍,而组织缺损患者SIB+IIB可降低1年大截肢或死亡风险。

要点

  • 静息痛患者联合腹股沟下血运重建围术期大截肢风险增加约2.8倍。
  • 组织缺损患者SIB+IIB较单独SIB降低1年大截肢或死亡风险47%。
  • 组织缺损患者中SIB+IIB优于SIB+IIPVI。

核心结论

  • 静息痛患者SIB联合腹股沟下血运重建与截肢风险增加相关,应限制使用。
  • 组织缺损患者SIB+IIB与截肢或死亡风险降低相关,可能优先于SIB+IIPVI。

研究设计与样本

  • 回顾性队列研究,纳入VQI数据库2010年1月至2020年6月接受SIB的CLTI患者8037例。
  • 分组:单独SIB 6537例(81.3%),SIB+IIB 783例(9.7%),SIB+IIPVI 717例(8.9%)。
  • 手术指征:静息痛5040例(62.5%),组织缺损3031例(37.6%)。

主要发现

  • 三组30天死亡率和围术期心肌梗死率无显著差异。

临床怎么用

  • 静息痛患者应避免常规联合腹股沟下血运重建,遵循现行指南。
  • 组织缺损患者可优先考虑SIB+IIB而非SIB+IIPVI。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Combined suprainguinal and infrainguinal revascularization is sometimes necessary in the treatment of patients with chronic limb-threatening ischemia (CLTI). However, data on outcomes of concomitant revascularization procedures are lacking. We studied the outcomes of patients with CLTI who underwent suprainguinal bypass (SIB) alone, SIB with concomitant infrainguinal bypass (IIB), and SIB with concomitant infrainguinal peripheral endovascular intervention (IIPVI). METHODS: We reviewed all patients in the Vascular Quality Initiative with CLTI who underwent SIB from January 2010 to June 2020. Logistic regression, Kaplan-Meier survival estimates, log-rank tests, and Cox regression were used to analyze outcomes. Outcomes were 30-day mortality, perioperative myocardial infarction, perioperative major amputation, 1-year amputation-free survival, and 5-year survival. RESULTS: Of 8037 patients included, 81.3% (n = 6537) underwent SIB alone, 9.7% (n = 783) underwent SIB+IIB, and 8.9% (n = 717) underwent SIB+IIPVI. The indication for surgery was rest pain in 5040 (62.5%) and tissue loss in 3031 (37.6%). There were no significant differences in 30-day mortality and perioperative myocardial infarction rates. However, there was 2.8-fold increased odds of perioperative major amputation in both SIB+IIPVI (odds ratio [OR], 2.76; 95% confidence interval [CI], 1.30-5.88; P = .008) and SIB+IIB (OR, 2.79; 95% CI, 1.38-5.54; P = .004) among patients with rest pain as compared with SIB alone. Comparing SIB+IIPVI with SIB alone, there were no significant differences in 1-year freedom from amputation and amputation-free survival. SIB+IIPVI was associated with a 27% increased risk of 5-year mortality (hazard ratio [HR], 1.27; 95% CI, 1.03-1.55; P = .035). Compared with SIB alone, SIB+IIB was associated with 97% increased risk of 1-year major amputation among patients with rest pain (HR, 1.97; 95% CI, 1.06-3.69; P = .033), but a 47% decreased risk of 1-year major amputation or death for patients with tissue loss (HR, 0.53; 95% CI, 0.37-0.78; P = .001). SIB+IIPVI, compared with SIB+IIB, was associated with a two-fold increased risk of 1-year major amputation or death (HR, 2.04; 95% CI, 1.04-2.23), P = .003) and a 52% increased risk of 5-year mortality (HR,1.52; 95% CI, 1.04-2.24; P = .032) among patients with tissue loss. CONCLUSIONS: This study shows that SIB with concomitant infrainguinal revascularization in patients with rest pain is associated with an increased risk of amputation, whereas SIB+IIB in patients with tissue loss is associated with decreased risk of amputation or death. SIB+IIB outperformed SIB+IIPVI in patients with tissue loss. SIB with infrainguinal revascularization should be limited in patients with rest pain in line with current guidelines, but SIB+IIB may be preferred in patients with tissue loss.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Naazie IN, Zarrintan S, Arhuidese I, et al. Contemporary outcomes of concomitant suprainguinal bypass with infrainguinal revascularization procedures in patients with chronic limb-threatening ischemia. J Vasc Surg. 2021. PMID: 34606957. doi:10.1016/j.jvs.2021.08.105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。